- Home
- UAL vs INSM Comparison
UAL vs INSM Comparison
Compare UAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- INSM
- Stock Information
- Founded
- UAL 1934
- INSM 1988
- Country
- UAL United States
- INSM United States
- Employees
- UAL N/A
- INSM N/A
- Industry
- UAL Air Freight/Delivery Services
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- UAL Consumer Discretionary
- INSM Health Care
- Exchange
- UAL Nasdaq
- INSM Nasdaq
- Market Cap
- UAL 32.0B
- INSM 29.0B
- IPO Year
- UAL N/A
- INSM 2000
- Fundamental
- Price
- UAL $94.04
- INSM $189.60
- Analyst Decision
- UAL Strong Buy
- INSM Strong Buy
- Analyst Count
- UAL 14
- INSM 19
- Target Price
- UAL $125.77
- INSM $171.12
- AVG Volume (30 Days)
- UAL 7.1M
- INSM 2.1M
- Earning Date
- UAL 10-15-2025
- INSM 10-30-2025
- Dividend Yield
- UAL N/A
- INSM N/A
- EPS Growth
- UAL 20.30
- INSM N/A
- EPS
- UAL 9.99
- INSM N/A
- Revenue
- UAL $58,369,000,000.00
- INSM $447,022,000.00
- Revenue This Year
- UAL $4.73
- INSM $32.08
- Revenue Next Year
- UAL $7.73
- INSM $125.86
- P/E Ratio
- UAL $9.42
- INSM N/A
- Revenue Growth
- UAL 4.24
- INSM 30.34
- 52 Week Low
- UAL $52.00
- INSM $60.40
- 52 Week High
- UAL $116.00
- INSM $197.08
- Technical
- Relative Strength Index (RSI)
- UAL 42.70
- INSM 76.69
- Support Level
- UAL $92.34
- INSM $154.79
- Resistance Level
- UAL $100.69
- INSM $168.22
- Average True Range (ATR)
- UAL 4.05
- INSM 6.44
- MACD
- UAL -0.58
- INSM 1.81
- Stochastic Oscillator
- UAL 12.05
- INSM 82.31
About UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.